Department of Neurological Surgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania.
Department of Neurological Surgery, Arkansas Neuroscience Institute, CHI St. Vincent, Little Rock, Arkansas.
Oper Neurosurg (Hagerstown). 2019 Jul 1;17(1):8-13. doi: 10.1093/ons/opy301.
The use of the pipeline embolization device (PED; Medtronic, Dublin, Ireland) in the posterior circulation has been limited and infrequently reported compared to other off-label utilizations. Posterior inferior cerebellar artery aneurysms (PICAA) constitute 1 of the least reported posterior circulation aneurysms treated with PED. No clinical studies have addressed the treatment of these aneurysms with flow diversion exclusively.
To appraise the feasibility and the safety of PED in the treatment of PICAAs.
Data on 12 consecutive patients, treated between 2011-2017 with PED for their PICAA, was retrospectively reviewed. To control confounding, we used multivariable logistic regression and propensity score conditioning.
Of 534 patients, 12 (9/12, 75% males) were identified and constituted our study population. The average aneurysm size was 8.47 mm (SD = 2.6, 3.7-14). Patients were followed-up for an average of 10.3 months (SD = 11 mo). Two of 12 (16.7%) had a prior history of subarachnoid hemorrhage. Eight of 12 (67%) of the aneurysms were saccular, 3/12 (25%) were dolichoectatic, and 1/12 (8%) was a small blister aneurysm. Eleven of 12 (92%) aneurysms were treated with 1 PED; 2/12 (16.7%) patients received combined pipeline assisted coiling. All patients had a complete occlusion, regression, and resolution of their aneurysm(s). PED deployment was neither complicated with any hemorrhagic or clinically significant thromboembolic events nor with device migration in any of our patients. Three of 12 (25%) patients had a benign intrastent stenosis. No mortality, among our 12 patients, was noted throughout the follow-up period.
PED, deployed by specialized experts, should be safe in treating PICAA. It can be contemplated as a novel alternative treatment of aneurysms located at the PICA-VA bifurcation or within the PICA.
与其他超适应证应用相比,Pipeline 栓塞装置(PED;爱尔兰都柏林美敦力公司)在后循环中的应用较为有限且报道较少。后下小脑动脉动脉瘤(PICAA)是报道较少的接受 PED 治疗的后循环动脉瘤之一。尚无临床研究专门探讨使用血流导向装置治疗这些动脉瘤。
评估 PED 治疗 PICAA 的可行性和安全性。
回顾性分析了 2011 年至 2017 年间 12 例连续接受 PED 治疗的 PICAA 患者的数据。为了控制混杂因素,我们使用多变量逻辑回归和倾向评分匹配。
在 534 例患者中,有 12 例(9/12,75%为男性)被确定为研究对象。平均动脉瘤大小为 8.47mm(标准差=2.6,3.7-14)。患者平均随访 10.3 个月(标准差=11 个月)。12 例患者中有 2 例(16.7%)有蛛网膜下腔出血史。12 例中的 8 例(67%)为囊状动脉瘤,3 例(25%)为梭形动脉瘤,1 例(8%)为小泡状动脉瘤。12 例患者中有 11 例(92%)采用 1 个 PED 治疗,2 例(16.7%)患者接受联合Pipeline 辅助弹簧圈栓塞。所有患者的动脉瘤均完全闭塞、缩小和消失。PED 植入术未发生任何出血性或有临床意义的血栓栓塞并发症,也未发生任何器械移位。12 例患者中有 3 例(25%)出现良性支架内狭窄。在整个随访期间,我们的 12 例患者均无死亡。
PED 由专业专家植入,治疗 PICAA 应是安全的。对于位于 PICA-VA 分叉处或 PICA 内的动脉瘤,PED 可作为一种新的治疗选择。